A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2017-06-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-16-0660PMID 28655785PMCID PMC5628125
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.

  2016cited by this paper
• Introduction to the review series on advances in acute myeloid leukemia (AML).

  2016cited by this paper
• Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.

  2016cited by this paper
• PARP inhibitors: a treatment option for AML?

  2015cited by this paper
• FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

  2015cited by this paper
• Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia

  2015cited by this paper
• mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer

  2015cited by this paper
• Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors.

  2015cited by this paper
• Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors

  2015cited by this paper
• AZD1775 sensitizes T cell acute lymphoblastic leukemia cells to cytarabine by promoting apoptosis over DNA repair

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma

  2014cited by this paper
• Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

  2014cited by this paper
• Abrogating G2/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma

  2014cited by this paper
• DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance

  2014cited by this paper
• The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells

  2013influential reference
• Inhibition of Wee1 Sensitizes Cancer Cells to Antimetabolite Chemotherapeutics In Vitro and In Vivo, Independent of p53 Functionality

  2013influential reference
• Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination

  2013influential reference
• Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy

  2013cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia.

  2012cited by this paper
• High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy

  2012cited by this paper
• Clinical and laboratory biology of childhood acute lymphoblastic leukemia.

  2012cited by this paper
• Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.

  2011cited by this paper
• Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and novel therapeutic target in acute myeloid leukemia

  2011cited by this paper
• Biology, risk stratification, and therapy of pediatric acute leukemias: an update.

  2011cited by this paper
• The treatment of elderly patients with acute myeloid leukemia.

  2011cited by this paper
• MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

  2011cited by this paper
• Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease

  2011cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs

  2010cited by this paper
• MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

  2010cited by this paper
• Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial.

  2010cited by this paper
• Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy.

  2010cited by this paper
• PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombination

  2009cited by this paper
• Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

  2009cited by this paper
• Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

  2009cited by this paper
• Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• Anthracycline dose intensification in acute myeloid leukemia.

  2009cited by this paper
• 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

  2008cited by this paper
• Internal tandem duplication of FLT3 (FLT3/ITD) induces increased ROS production, DNA damage, and misrepair: implications for poor prognosis in AML.

  2008cited by this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008influential reference
• p53 Mediates Senescence-Like Arrest Induced by Chronic Replicational Stress

  2007cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005influential reference
• Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination.

  2003cited by this paper
• Statistics of the Comet assay: a key to discriminate between genotoxic effects.

  2003cited by this paper
• Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis

  2003cited by this paper
• Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.

  2001cited by this paper
• [Treatment of elderly patients with acute myeloid leukemia].

  1997cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Cellular senescence in cancer: Friend or fraud?

  2026cites this paper
• Preclinical evaluation of the antitumoral efficacy of Wee1 inhibitor AZD1775 in adrenocortical carcinoma.

  2025cites this paper
• Targeting the DNA damage response in hematological malignancies

  2024cites this paper
• Therapeutic targeting of PARP with immunotherapy in acute myeloid leukemia

  2024cites this paper
• Inhibitors of the tyrosine kinases FMS-like tyrosine kinase-3 and WEE1 induce apoptosis and DNA damage synergistically in acute myeloid leukemia cells.

  2024cites this paper
• Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia

  2023cites this paper
• Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies

  2023cites this paper
• Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage

  2023cites this paper
• Design and synthesis of the first PARP-1 and proteasome dual inhibitors to treat breast cancer.

  2023cites this paper
• HDAC11 mediates the ubiquitin-dependent degradation of p53 and inhibits the anti-leukemia effect of PD0166285

  2023cites this paper
• Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

  2023cites this paper
• Ovarian cancer treatment strategies: focus on PARP inhibitors

  2023cites this paper
• New Approaches Towards Targeted Therapy for Childhood Neuroblastoma

  2023cites this paper
• Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma

  2023cites this paper
• Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

  2022cites this paper
• Sesquiterpene Lactones Potentiate Olaparib-Induced DNA Damage in p53 Wildtype Cancer Cells

  2022cites this paper
• Targeting replication stress in cancer therapy

  2022cites this paper
• Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells

  2022cites this paper
• Cellular senescence signaling in cancer: A novel therapeutic target to combat human malignancies.

  2022cites this paper
• Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies

  2022cites this paper
• BMP2/SMAD pathway activation in JAK2/p53-mutant Megakaryocyte/Erythroid Progenitors Promotes Leukemic Transformation.

  2022cites this paper
• Perspectives on PARP Inhibitor Combinations for Ovarian Cancer

  2021cites this paper
• PARP Inhibitors and Haematological Malignancies—Friend or Foe?

  2021influential citation
• PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

  2021cites this paper
• Current evidences of BRCA mutations in genitourinary and gynecologic tumors: a scoping review

  2021cites this paper
• Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration

  2021cites this paper
• PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology

  2021cites this paper
• New treatment strategy for ovarian cancer with a BRCA gene mutation

  2021cites this paper
• Targeting Wee1 kinase as a therapeutic approach in Hematological Malignancies.

  2021cites this paper
• Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors

  2020cites this paper
• Advances in the treatment of ovarian cancer using PARP inhibitors and the underlying mechanism of resistance.

  2020cites this paper
• Targeted therapies in gynaecological cancers

  2020cites this paper
• WEE1 inhibition induces glutamine addiction in T-cell acute lymphoblastic leukemia

  2020cites this paper
• Design, Synthesis, and In Vitro Evaluation of the Photoactivatable Prodrug of the PARP Inhibitor Talazoparib

  2020cites this paper
• WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma

  2020cites this paper
• Synergy between Non-Thermal Plasma with Radiation Therapy and Olaparib in a Panel of Breast Cancer Cell Lines

  2020cites this paper
• WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.

  2020cites this paper
• Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia

  2020cites this paper
• The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review

  2020influential citation
• Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells.

  2020cites this paper
• Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.

  2020cites this paper
• Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond

  2020cites this paper
• Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy

  2020cites this paper
• University of Groningen WEE1 inhibition synergizes with CHOP chemotherapy and radiation therapy through induction of premature mitotic entry and DNA damage in diffuse large B-cell lymphoma de Jong,

  2020cites this paper
• Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

  2020cites this paper
• PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.

  2020cites this paper
• PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review

  2020cites this paper
• Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer

  2020cites this paper
• Structure-activity relationships of Wee1 inhibitors: A review.

  2020cites this paper
• A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target

  2020cites this paper
• Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials

  2020cites this paper
• XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

  2020cites this paper
• Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers

  2019cites this paper
• Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia

  2019cites this paper
• ROLE OF c-MET and EGFR IN ACQUIRED RESISTANCE TO PARP INHIBITORS IN TRIPLE-NEGATIVE BREAST CANCER

  2019cites this paper
• Overcoming Resistance to PARP Inhibition

  2019cites this paper
• GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens

  2019cites this paper
• PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

  2019cites this paper
• Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer

  2018cites this paper
• KLHL5 knockdown increases cellular sensitivity to anticancer drugs

  2018cites this paper
• The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer

  2018cites this paper
• Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis

  2018cites this paper
• AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations

  2018cites this paper
• Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.

  2018cites this paper
• Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach

  2018cites this paper
• Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer

  2017cites this paper
• PARP inhibitors: Clinical utility and possibilities of overcoming resistance.

  2017cites this paper